Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06472245 · ClinicalTrials.gov registry record · Phase 3
Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor
A Phase 3 study of Patients With Non-Small Cell Lung Cancer, sponsored by OSE Immunotherapeutics.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 363
- Enrollment target
- 20
- Study locations
NCT06472245 is a Phase 3 study of Patients With Non-Small Cell Lung Cancer that is actively recruiting participants, run by OSE Immunotherapeutics. The registered enrollment target is 363 participants. The trial reports 20 study locations across 5 states.
The verdict
NCT06472245, a Phase 3 study of Patients With Non-Small Cell Lung Cancer, is actively recruiting participants, sponsored by OSE Immunotherapeutics.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 363 participants
- Enrollment target
- 20
- Study locations
Study Summary
Multicenter, randomized (2:1), open-label phase 3 study in HLA-A2 positive patients with squamous and non-squamous metastatic NSCLC with ICI secondary resistance. Patients will be randomized into 2 arms (randomization 2:1): experimental Arm A with OSE2101 monotherapy or control Arm B SoC with docetaxel monotherapy. Stratification factors will be histology (squamous versus non squamous) and ECOG Performance Status (0 versus 1).
Conditions Studied
Interventions
- DRUG Docetaxel
- DRUG OSE2101
- DEVICE NGS HLAA2 assay
Study Locations (20)
Florida
- Comprehensive Hematology Oncology - Bradenton Clinic - Bradenton
- Comprehensive Hematology Oncology - Brandon Clinic - Brandon
- Cancer Specialists of North Florida - Fleming Island - Fleming Island
- Cancer Specialists of North Florida - Riverside - Jacksonville
- Cancer Specialists of North Florida Southside - Jacksonville
- Cancer Specialists of North Florida - Northside - Jacksonville
- Cancer Specialists of North Florida - Southpoint - Jacksonville
- Cancer Specialists of North Florida - Baptist South - Jacksonville
- Cancer Specialists of North Florida - Jacksonville Beach
- Comprehensive Hematology Oncology - Largo Clinic - Largo
- Cancer Specialists of North Florida - Beaches - Neptune Beach
- Comprehensive Hematology Oncology - Palm Harbor Clinic - Palm Harbor
California
- Clinical Research Advisors, LLC - Beverly Hills
- Clinical Research Advisors - Encino - Encino
- Clinical Research Advisors - West Hollywood - Los Angeles
- Clinical Research Advisors - Korea Town - Los Angeles
Colorado
- SCL Health - Saint Joseph Hospital Cancer Center - Littleton
- Lutheran Medical Center - Cancer Centers of Colorado - Wheat Ridge
Connecticut
- Eastern Connecticut Hematology and Oncology Associates - Norwich
District of Columbia
- Georgetown Lombardi Comprehensive Cancer Center - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 363 participants |
| Start Date | 2024-12-03 |
| Est. Completion | 2028-12-15 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06472245
The ClinicalTrials.gov registry entry for NCT06472245 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 363 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is OSE Immunotherapeutics, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Patients With Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 3 interventions - of which Docetaxel is the first listed.
NCT06472245 reports 20 study locations spanning 5 distinct geographic areas - top geographies include Florida, California, Colorado.
Frequently Asked Questions
What is clinical trial NCT06472245 about?
NCT06472245 is a clinical study titled "Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor". Multicenter, randomized (2:1), open-label phase 3 study in HLA-A2 positive patients with squamous and non-squamous metastatic NSCLC with ICI secondary resistance. Patients will be randomized into 2 arms (randomization 2:1): experimental Arm A with OSE2101 monotherapy or control Arm B SoC with docet...
What is the current status of trial NCT06472245?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 363 participants. The study started on 2024-12-03. Estimated completion is 2028-12-15.
What conditions does trial NCT06472245 study?
This clinical trial studies the following conditions: Patients With Non-Small Cell Lung Cancer.
What interventions are being tested in trial NCT06472245?
The interventions under investigation include: Docetaxel (DRUG), OSE2101 (DRUG), NGS HLAA2 assay (DEVICE).
Who is sponsoring clinical trial NCT06472245?
This trial is sponsored by OSE Immunotherapeutics, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06472245 being conducted?
This trial has 20 study locations across California, Colorado, Connecticut, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.